← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Contact laxatives
dantron, combinations
A06AB53
Forms & Strengths
- Combination oral tablets containing dantron (danthron) and docusate sodium
- Typical ratio: dantron 50 mg with docusate sodium 60 mg per tablet
Adult Dosing
- 1 to 2 tablets daily, typically taken at bedtime
- Adjust dose based on clinical response and bowel regularity
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
- Generally not recommended for use in children
Indications
- Short-term treatment of occasional constipation
- Management of opioid-induced constipation where stimulant and stool softener combination is indicated
Mechanism of Action
- Dantron acts as a stimulant laxative, directly stimulating colonic peristalsis and altering electrolyte secretion
- Docusate sodium acts as an anionic surfactant, lowering surface tension to allow water and fats to penetrate and soften stool
Contraindications
- Known hypersensitivity to dantron, docusate, or anthraquinones
- Symptoms of appendicitis, intestinal obstruction, or undiagnosed abdominal pain
- Fecal impaction and acute surgical abdomen
- Severe dehydration
Adverse Reactions
- Abdominal discomfort, cramping, and colic
- Mild diarrhea with excessive dosing
- Melanosis coli (benign pigmentation of the colonic mucosa with prolonged use)
- Discoloration of urine (pink/red or yellowish-brown depending on urinary pH)
Drug Interactions
- Mineral oil: Concurrent use may increase absorption of mineral oil, leading to adverse systemic effects
- Cardiac glycosides: Laxative-induced potassium loss may potentiate digoxin toxicity
- Diuretics: Increased risk of hypokalemia when combined with potassium-wasting diuretics
Curated Content: Needs Vetting Before Put to Clinical Use